Paradigm Biopharmaceuticals completes Zilosul dosing under FDA’s Expanded Access Program
ShareRoot plans Opyl transformation under leadership of Michelle Gallaher and Julian Chick
Admedus makes "transformational" sale of CardioCel and VascuCel for $36.2 million
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.